Supplementary Materials and Methods
Cell Lines CE1-4 cell line is a clonal cell line derived from the murine castration-resistant prostate tumor cell line CE1 (provided by Dr. Pradip Roy-Burman) (1) . CE1-4 and its subclonal lines derived from orthotopic mouse models were cultured in DMEM medium supplemented with 10% FBS, 100 U/ml Penicillin, and 100 µg/ml Streptomycin. Normal human lung fibroblasts (NHLF), dermal fibroblasts (DF), human umbilical vein/vascular endothelial cells (HUVEC), PC3, VCaP, LNCaP and 22RV1 were obtained and authenticated from ATCC (by STR profiling), and maintained as recommended. RMF is a cancer associated fibroblast (CAF) line derived from a breast cancer patient as described previously (2) . Cultured breast CTC cell lines BRx07, BRx50, and BRx42 were grown in suspension in ultra-low attachment plates (Corning) in tumor sphere medium (RPMI-1640, EGF (20 ng/ml), bFGF (20 ng/ml), 1X B27, 1X antibiotic/antimycotic (Life Technologies)) under hypoxic (4% O2) conditions (3) . All cell lines were routinely checked for mycoplasma, using a mycoplasma detection kit (MycoAlert, Lonza).
Derivation of Stable Cell Lines
Plenti-Inducer kit was acquired from Dr. Stephen Elledge (4) . Prlr CDS was amplified by PCR using MGC mouse Prlr cDNA as a template and cloned into pInducer20 using a gateway cloning system pENTR/D-TOPO kit (Life Technologies). Transfection of 293T cells was performed using lipofectamine 2000 (Life Technologies). pInducer20-Prlr (10 µg) was co-transfected with lentiviral packaging plasmids pCMV-dR8.91(10 µg) and pCMV-VSVG (2.5 µg) into one 10 cm plate of 293T cells at 80% confluence. Lentivirus was collected 48 and 72 hours later. CE1-4 cells were infected with lentivirus in the presence of 8 µg/ml polybrene for 24 hours and then selected in growth medium containing 100 µg/mL G418 for 7 days. Lentiviral constructs pWPI-Luc-GFP and pUltra-hot (mCherry) were used to generate CE1-4 cells stably expressing Luc-GFP and/or mCherry in a similar procedure except the final selection step, where the positive cells were selected by FACS. For the shRNA encoding vectors, pLKO1-shTRC (control-named shSCR), shNR4A1 (clone C8 TRCN0000019425, and clone C9 TRCN0000019426), shNR4A2 (clone D7 TRCN0000236384 and clone D9 TRCN0000236383), shNR4A3 (clone TRCN0000019560 and clone G7 TRCN0000019562), shRXRa (clone F4 TRCN0000021617 and clone F5 TRCN0000021618) were obtained from the Broad Institute TRC library and transfected in 293T cells using X-tremeGene (ROCHE). Plasmids were co-transfected with lentiviral packaging plasmids pCMV-dR8.91 (10 µg) and pCMV-VSVG (2.5 µg) into one 10 cm plate of 293T cells at 80% confluence. Lentivirus was collected 48 and 72 hours later. DF cells were infected with lentivirus in the presence of 8 µg/ml polybrene for 24 hours and then selected in growth medium containing 2 µg/mL Puromycin for 3 days.
Mouse Models
Animal experiments were performed in accordance with institutional guidelines at the Massachusetts General Hospital and approved by the animal protocol (IACUC 2010N000006). CE1-4 cells (1x106) stably expressing luciferase and GFP were orthotopically introduced into the prostate of immunodeficient NSG mice and monitored weekly using the Xenogen IVIS Spectrum in vivo imaging system. Data was analyzed using IVIS Lumina Living Image 4.2 according to the manufacturer's instructions. IVIS luminescence signal was normalized to photon (p/sec/cm2/sr), and total photon count in the region of interest was quantified using the ROI function of the software. For Prlr overexpression experiments, CE1-4 cells (1x106) stably expressing mCherry as well as the doxycycline inducible Pinducer20-Prlr were orthotopically introduced into the prostate of immunodeficient NSG mice. Doxycycline was added to the drinking water (1 mg/ml).
For the intratibial tumor model, 250 CE1-4 cells expressing mCherry and GFP/luciferase were injected intratibially into NSG mice (N=12 tibias per group). Mice were pretreated with celecoxib for 24 hours before tumor cell inoculation, and then continuously treated with celecoxib for 8 weeks (25 mg/kg, oral, daily for eight weeks). Mice were sacrificed and mouse tibia were collected, sectioned, and evaluated for tumor occurrence.
Single Cell Collection and RNA-Seq
Mouse blood was collected at 6-7 or 9-11 weeks after tumor cell inoculation, and CTCs were isolated using the CTC iChip (24). Metastases were dissected out from the lung under a fluorescence dissection microscope. The rest of the lung tissue was digested into single cells by collagenase and hyaluronidase (Stemcell Technologies), which were then sorted by FACS to enrich for GFP-positive STCs. Primary tumor and lung metastases were also digested into single cells using the same procedure. The GFP-positive tumor cells from each category (CTC, STC6, STC9-11, Primary, Mets) were individually micromanipulated using a 10 µm transfer tip on an Eppendorf TransferMan NK 2 micromanipulator. A complete single-cell sample list is provided in Dataset S1. For ex-vivo culture of lung STC, mice were sacrificed 6 weeks after orthotopic inoculation of 1x106 luciferase-GFP expressing CE1-4 cells into the prostate. Lung tissues were minced and digested into single cells using collagenase and hyaluronidase. Single cells were filtered through a 70 µm cell strainer and then a 40µm cell strainer before FACS enrichment. FACS-sorted GFP positive tumor cells were cultured in 3 cm culture dishes using complete DMEM medium supplemented with 10% FBS for at least two weeks to establish lung STC lines. One million cells from multiple lung STC cultures were subcutaneously introduced into the flanks of NSG mice to test their tumorigenic ability. Eight weeks after inoculation, mice were sacrificed and tumors were measured for the maximum diameter. For single-cell RNA-Seq, whole transcriptome amplification was performed using SMARTer v3 Ultra Low Input RNA Kit (Clonetech), and cDNA library preparation was performed using Nextera XT Kit (Illumina). Sequencing was performed on the Illumina HiSeq2500 platform.
Bulk RNAseq
For bulk RNA-Seq, total RNA was isolated from cell lines using RNeasy Mini Kit (Qiagen). Library was prepared using TruSeq Stranded Total RNA Library Prep Kit (Illumina) following low sample protocol and sequenced on Illumina NextSeq 500 platform. Trimmomatic was used to crop read lengths to 50 nucleotides, and to remove the TruSeq3-PE-2 Illumina adapters. The paired-end reads were then aligned using tophat2 and bowtie1 with the no-novel-juncs argument. Reads that did not align or that aligned to multiple locations were discarded. The number of reads aligning to each gene was then determined using htseq-count. Samples that had fewer than 3x10 5 uniquely aligned and counted reads were discarded. The read count for each gene was divided by the total counts assigned to all genes and multiplied by one million to form the reads per million (RPM). Fragments-per-kilobase-million (FPKM) counts were determined by submitting the tophat2 output to Cufflinks.
RNAseq bioinformatic analysis
To perform supervised differential gene expression for single cells from different categories, we first discarded genes for which the 90th percentile of RPM was less than 10. For each remaining gene, we performed a t-test and then corrected for multiple hypothesis testing by the Benjamini-Hochberg (BH) method. We called differentially expressed those genes for which the BH q-value was less than 0.25 and the fold-change was greater than 2. Unsupervised clustering was hierarchical with average linkage and metric equal to (1 -r), where r is the Pearson correlation coefficient. Gene-Set Enrichment Analysis (GSEA) analyses were performed using version 2.0.14 of the gsea2 software (www.broadinstitute.org/gsea) and the BIOCARTA subset of version 4.0 of MSigDB. Metascore is the mean log10(RPM + 1) for the genes shown in the heatmaps except for the glycolysis metascore, which is computed using the mean log10(RPM + 1) for the genes in the BIOCARTA_GLYCOLYSIS_PATHWAY gene set of the 4.0 version of MSigDB (www.broadinstitute.org/gsea/msigdb). To identify the cytokine receptor that promotes the proliferation of STCs, we first found 127 cytokine receptors that are expressed in our single-cell RNA-Seq dataset. Student's t-tests were performed on these 127 genes to test the null hypothesis that there is no differential expression in two groups of single cells (primary and STC6, versus STC9-11 and Mets). 18 genes meeting the following criteria (p-value < 0.05, FDR<0.25, median expression > 0) were plotted using Prism 7. All 1284 genes in the mouse secretome expressed in CE1-4 and its derived cell lines were used to perform unsupervised hierarchical clustering analysis. Student's t-tests were performed on these genes to test the null hypothesis that there is no differential expression in the two groups of cell lines, which were divided by the ability of their derived CM to induce PRL expression in fibroblasts. 40 out of 1284 genes were differently expressed in the two groups with a p-value lower than 0.05.
In Vitro Culture
For reconstitution experiments, tumor conditioned medium was prepared as follows. Fresh DMEM growth media (10 ml) was added to a 10 cm plate of CE1-4 cells. After 48 hours, tumor conditioned media were collected, passed through a 0.2 µm filter, and added to fibroblasts. During PGE-2 treatment, fibroblasts were grown in normal medium for 48 hours to exponential phase, then treated with the recommended concentration of 10 ng/ml PGE-2 (Sigma Aldrich # P0409) for the indicated time. DF cells were treated with NR4A1 inhibitor [Dim-c-pPhCo2Me (SIGMA) at 10 µM] and RXR inhibitor (HX531 (Fisher Scientific) at 1 um), 18 hours prior to PGE-2 treatment (10 ng/ml).
ChIP-Seq
ChIP assays were carried out using approximately 2-5 million cells per sample and per epitope, following the procedures described previously (63). In brief, chromatin from formaldehyde-fixed cells was fragmented to a size range of 200-700 bases with a Branson 250 sonifier. Solubilized chromatin was immunoprecipitated with an antibody recognizing H3K27ac (Active Motif #39133) overnight at 4°C. Antibody-chromatin complexes were pulled down with protein G-Dynabeads (Life Technologies), washed, and then eluted. After crosslink reversal, RNase A, and proteinase K treatment, immunoprecipitated DNA was extracted with AMP Pure beads (Beckman Coulter). ChIP DNA was quantified with Qubit. 1-5 ng ChIP DNA samples were used to prepare sequencing libraries, and ChIP DNA and input controls were sequenced using the Nextseq 500 Illumina genome analyzer.
ChIP-seq Bioinformatic Analysis
Reads were aligned to hg19 using bwa (5) . Aligned reads were then filtered to exclude PCR duplicates and were extended to 200 bp to approximate fragment sizes. Density maps were generated by counting the number of fragments overlapping each position using igvtools and normalized to 10 million reads. We used macs2 (6) to call H3K27ac peaks in treated cells using matching input controls with a q-value threshold of 0.0001 and the --broad parameter. Peaks within 200 bp of each other were merged and were filtered to exclude blacklisted regions as defined by the ENCODE consortium (7) . Only overlapping regions identified in two independent experiments using the GenomicRanges Bioconductor package (8) were considered for further analyses. Average ChIP-seq signals across intervals were calculated using bwtool (9) and we selected H3K27ac peaks showing 3 fold or more increased levels in treated cells when compared to control cells in two independent experiments. H3K27ac ChIP-seq peaks were considered promoter peaks if they were within 1 kb of transcriptional start sites (TSSs) in the Refseq database, distal peaks were then annotated as intragenic or intergenic using the Refseq gene bodies coordinates and associated with the closest gene using GenomicRanges (8) . Signals shown in composite plots were calculated using bwtool (9) . For motif discovery, we used Homer suite of tools (10) . findMotifsGenome.pl was used to identify de novo motifs within H3K27ac peaks.
Immunofluorescence
Sections of paraffin-embedded primary tumor and lung metastases were deparaffinized and hydrated. Antigen retrieval by citric acid buffer with high heat was performed. For dual-color IF, slides were incubated with 0.05% sudan black solution in 70% ethanol. Slides were blocked with avidin/biotin blocking kit and normal goat serum, and then incubated with primary antibodies against GFP (Abcam, EPR14104, 1:250), Ki67 (BD Biosciences, B56, 1:250), Prlr (Abcam, ab2772, 1:200), mCherry (Abcam, 1C51, 1:500), mPRL (MAB1445, 1:200), p-Akt Thr308 (Cell Signaling, D25E6, 1:100), p-Erk1/2 (Cell Signaling, D13.14.4E, 1:100), p-Stat3 (Cell Signaling, D3A7, 1:100), or p-Stat5 (Cell Signaling, C11C5, 1:100) at 4 degrees overnight. For p-Stat and Ki67 staining, biotinylated secondary antibody (Vector Laboratories, 1:200) coupled with Fluoroscien Avidin DCS (Vector Laboratories, 1:500) was used to amplify the signal. For all other markers, secondary IgG antibodies conjugated with fluorophores 488 or 555 were used (Life Technologies, 1:500). All slides were imaged on the Nikon Eclipse 90i microscope. At least three highpower fields (hpf) were randomly selected from each slide for quantification. The number of lung metastases was quantified based on the size of the lesion (1-5 cells; 6-20 cells; 20+ cells).
Immunohistochemistry
Sections of paraffin-embedded primary tumor, lung, lymph nodes, brain, livers and bone metastases of human and mouse models, as well as human tumor microarray samples were deparaffinized and hydrated. Antigen retrieval by citric acid buffer with high heat was performed. For GFP staining, slides were blocked with normal goat serum and incubated with anti-GFP antibody (Abcam, EPR14104, 1:250) in PBS containing 1% BSA at 4 degrees overnight. Slides were blocked with avidin/biotin blocking kit, and then incubated with biotinylated secondary antibody (Vector Laboratories, 1:200) for 30 minutes. For mCherry or PRL staining, slides were blocked with BLOXALL (Vectorlabs), and incubated with mCherry (Abcam, 1C51, 1:500), hPRL (Biorad, 0100-0665, 1:6000) in diluent buffer (Vectorlabs) at 4 degrees overnight. Slides were then incubated with HRP secondary antibody (Vector Laboratories, 1:200) for 30 minutes. DAB substrate was used to amplify and visualize the signal. Slides were counterstained with Hematoxylin, dehydrated, and sealed with VectaMount permanent mounting medium. Images were acquired on the Aperio ScanScope system (Leica Biosystems). For all IHC analysis, a specimen was considered positive if it had >10% of cells in the appropriate compartment stained. For reanalysis of proteinatlas.org IHC data, we evaluated antibody CAB000113 (Thermo Fisher Scientific) for COX-2 (PTGS2). This antibody is validated by proteinatlas.org through assessment of staining pattern in 44 normal tissues, and the antibody was approved for IHC, indicating the staining is consistent with protein/gene characterization data in the literature. We evaluated antibody CAB023353 (Bio-Rad) for PRL. This antibody is validated in the same way, and is considered supported for IHC, indicating the staining is consistent with both RNA expression data and protein/gene characterization data in the literature. For evaluation of PRL staining, we excluded specimens that did not have observable stroma.
RNA in situ Hybridization (RNA-ISH)
RNA in situ Hybridization on mouse tumor tissue was performed using the Affymetrix ViewRNA ISH Tissue Assay Kit (11) . Type 1 probe for Prlr (VB1-19573) was used at 1:50. RNA in situ Hybridization on human tumor tissue was performed using the ACD probe against human PRLR (542558) using the standard C1 design following standard protocols. Briefly, paraffin-embedded tissue blocks were freshly cut and frozen at -80°C until staining. Upon removal from the freezer, slides were baked for 1 hr at 60°C. Slides were treated with Histo-Clear to remove paraffin. Slides were imaged on the Aperio microscopy system (40x objective) within 1 week of staining to maintain a digital pathology archive of specimens. Cells with at least three red dots were classified as Prlr positive tumor cells. Specimens were considered positive if >10% of cells had positive signal.
Cell Proliferation Assay 2x10 3 CE1-4 cells were plated in each well of a 96-well plate in a volume of 100 μl growth medium with or without 250 ng/ml doxycycline or 100 ng/ml Prl. At indicated time points, cell proliferation was measured with CellTiter-Glo reagent, added 1:1 to sample volume according to manufacturer's protocol. Luminescence was read with SpectraMax M5 plate reader.
Quantitative real-time PCR
Total RNA was extracted from cell pellets or homogenized lung tissue using RNeasy Mini Kit (Qiagen). 1 µg of RNA was used to generate cDNA using SuperScript III First Strand synthesis system (Life Technologies). Reactions were amplified and analyzed in triplicate using the ABI 7500 Real-Time PCR System. A housekeeping gene GAPDH was used as an internal control. Primers for human GAPDH: 
ELISA Assays
Parameter PGE-2 ELISA assay (R&D Systems, KGE004B) was performed according to manufacturer's protocol. Briefly, 150 µl of each sample was added into the well of a 96-well microplate coated with anti-PGE-2 primary antibody. HRP-conjugated PGE-2 was added to bind with the remaining antibody. A substrate solution was added to determine the amount of bound PGE-2-HRP conjugate. Optical density was read at 450 nm and 540 nm on SpectraMax M5 plate reader. The concentration of PGE-2 in each sample was calculated based on the standard curve generated using PGE-2 standards provided in the kit. PRL ELISA assay (Cayman Chemical, 500730) was performed according to manufacturer's protocol. Media was harvested from fibroblasts after 24-hour incubation with tumor conditioned media or exogenous PGE-2 and Msln. Samples were added into the well of a 96-well microplate coated with streptavidin, together with a solution containing biotinylated capture antibody against PRL. HRP-labeled detection antibodies against a different epitope on PRL were then added, and the tetramethylbenzidine substrate solution was used to yield colorimetric output that could be read by SpectraMax M5 plate reader at 450 nm.
Meta analysis
To compare the expression of the PRLR gene in unpaired primary and metastatic tumors, we performed meta-analysis. The treatment effect was defined as the difference in means between primary and metastasis divided by the combined within-class standard deviation. A test of heterogeneity was performed and if the resulting p-value was less than 0.05 (which in this case it was), we fit a random effects model; otherwise, we fit a fixed effects model. Public datasets used in this analysis are listed in Table S1 .
Data Analysis
Unless indicated otherwise, data represent the mean of at least 3 independent experiments ± SD. P-values were determined using the two-tailed Student t-test by Graph-Pad Prism 7. For samples with >3 specimens, data are roughly normal-distributed. An estimate of variation within each group of data is done as part of the t-test. A difference was considered statistically significant if the p-value was equal to or less than 0.05. For the rodent experiments, post-hoc power analysis was performed using G*Power (12) to ensure that a negative result is meaningful, and that the number of mice used are sufficient, such that a positive result of given magnitude would have been detectable. For animal and cell line experiments, no randomization, no blinding, and no exclusion were done.
Data Availability
Single-cell and bulk-cell RNA-Seq data from prostate cancer mouse models and cell lines have been deposited in GEO under accession number GSE96676.
Tumor specimens and microarrays
Human normal and tumor tissues microarrays were generated from discarded excess tissue obtained from the Massachusetts General Hospital (MGH) and after being de-identified per MGH Institutional Review Board (IRB)-approved protocols (prostate: 2000P002109 and colon 2016P002541). 
